Article
Genetic and epigenetic heterogeneity and the impact on cancer relapse.
Experimental hematology - 1 Oct 2017
Hassan Ciaran, Afshinnekoo Ebrahim, Li Sheng, Wu Shixiu, Mason Christopher E
Abstract excerpt
Acute myeloid leukemia (AML) is an aggressive hematopoietic malignancy with an exceedingly poor prognosis: a 5-year overall survival rate of 40%-45% in the young and a 5-year survival rate of less than 10% in the elderly (>60 years of age). Although a high percentage of patients enters complete remission after chemotherapeutic intervention, the majority of patients relapse within 3 years. Such stark prognostic...
Topics
- Age Factors
- Antineoplastic Agents
- Chromosome Aberrations
- Drug Resistance, Neoplasm
- Epigenesis, Genetic
- Gene Expression Regulation, Leukemic
- Genetic Heterogeneity
- Humans
- Leukemia, Myeloid, Acute
- Mutation
- Neoplasm Proteins